CervoMed Announces Addition To Russell 2000 And Russell 3000 Indexes

6/24/24 8:03:09 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CRVO alert in real time by email

CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its expected addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective when the U.S. equity markets open on Monday, July 1, 2024, according to the final preliminary list of 2024 additions posted on the FTSE Russell website on June 21st 2024.

Get the next $CRVO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRVO

Date	Price Target	Rating	Analyst
12/17/2024		Buy → Neutral	H.C. Wainwright
12/11/2024		Buy → Neutral	Chardan Capital Markets
12/11/2024		Overweight → Underweight	Morgan Stanley
12/10/2024		Buy → Hold	D. Boral Capital
12/6/2024	$45.00	Buy	ROTH MKM
12/5/2024	$42.00	Buy	H.C. Wainwright
9/18/2024	$55.00	Buy	Chardan Capital Markets
7/26/2024	$35.00	Overweight	Morgan Stanley

More analyst ratings

$CRVO
Leadership Updates

Live Leadership Updates

CervoMed to Appoint William Elder as Chief Financial Officer
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him
5/20/24 8:00:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba
4/1/24 8:00:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp
2/7/24 8:30:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care

$CRVO
Press Releases

Fastest customizable press release news feed in the world

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch of neflamapimod — — Pharmacokinetic data obtained in a food-effect study in healthy volunteers in 4Q 2024 indicates that the new capsules achieved targeted mean plasma concentrations — — Within-subject comparison of certain participants who received older capsules during the double-blind phase of the RewinD-LB trial and new capsules in the open-label extension phase indicated that participants receiving newer batch capsules, on average, achieved targeted plasma concentration
1/31/25 8:00:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care
CervoMed to Present at the 8th International Lewy Body Dementia Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in deme
1/29/25 8:00:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (the "Company"), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees. On December 6, 2024, the Company granted options to purchase an aggregate of 14,753 shares of common stock to two new employees. Each option has an exercise price of $11.91, the closing price of the Company's common stock on the grant date, and each will vest in 36 equal installments on the last day of each month over a three-year period, subject to the employee's continued employment with the Co
12/12/24 7:00:00 AM ET
$CRVO
Biotechnology: Pharmaceutical Preparations
Health Care

CervoMed Announces Addition To Russell 2000 And Russell 3000 Indexes

Chat with this insight

Recent Analyst Ratings for
$CRVO

$CRVO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Gregoire Sylvie

SEC Form 4 filed by CFO & GC Elder William Robert

SEC Form 4 filed by Chief Operating Officer Cobuzzi Robert Joseph Jr.

$CRVO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by CervoMed Inc.

SEC Form SC 13G filed by CervoMed Inc.

SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

$CRVO
Leadership Updates

Live Leadership Updates

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

$CRVO
SEC Filings

CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$CRVO
Press Releases

Fastest customizable press release news feed in the world

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$CRVO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

$CRVO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

CervoMed downgraded by H.C. Wainwright

CervoMed downgraded by Chardan Capital Markets

CervoMed downgraded by Morgan Stanley

CervoMed Announces Addition To Russell 2000 And Russell 3000 Indexes

Chat with this insight

Recent Analyst Ratings for $CRVO

$CRVO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Gregoire Sylvie

SEC Form 4 filed by CFO & GC Elder William Robert

SEC Form 4 filed by Chief Operating Officer Cobuzzi Robert Joseph Jr.

$CRVO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by CervoMed Inc.

SEC Form SC 13G filed by CervoMed Inc.

SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

$CRVO Leadership Updates

Live Leadership Updates

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

$CRVO SEC Filings

CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$CRVO Press Releases

Fastest customizable press release news feed in the world

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$CRVO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

$CRVO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

CervoMed downgraded by H.C. Wainwright

CervoMed downgraded by Chardan Capital Markets

CervoMed downgraded by Morgan Stanley

Recent Analyst Ratings for
$CRVO

$CRVO
Insider Trading

$CRVO
Large Ownership Changes

$CRVO
Leadership Updates

$CRVO
SEC Filings

$CRVO
Press Releases

$CRVO
Insider Purchases

$CRVO
Analyst Ratings